Loading clinical trials...
Loading clinical trials...
A Phase II Study of Alemtuzumab in Combination With CHOP and ESHAP as First-Line Treatment in Peripheral T-Cell Lymphoma
Conditions
Interventions
CHOP regimen alternate with ESHAP regimen
Alemtuzumab
Locations
1
Thailand
King Chulalongkorn Memorial Hospital
Bangkok, Thailand
Start Date
January 1, 2005
Primary Completion Date
November 1, 2006
Completion Date
July 1, 2008
Last Updated
October 6, 2011
NCT06561048
NCT06909877
NCT07270861
NCT07072221
NCT05833724
NCT06855823
Lead Sponsor
King Chulalongkorn Memorial Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions